Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection.
de Wit E, Feldmann F, Cronin J, Jordan R, Okumura A, Thomas T, Scott D, Cihlar T, Feldmann H. · 2020
Read Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. by de Wit E, Feldmann F, Cronin J, Jordan R, Okumura A, Thomas T, Scott D, Cihlar T, Feldmann H. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7104368.txt.
Description
de Wit and co-authors tested the antiviral drug remdesivir against MERS coronavirus in rhesus monkeys, in the Proceedings of the National Academy of Sciences. MERS causes severe lung disease with a case fatality rate near 35%, and earlier candidate treatments had shown limited effect in animals. Remdesivir is a broad-acting antiviral.
Given before infection or after it, remdesivir lessened disease severity, cut virus replication, and reduced lung damage. The results made it a promising candidate for human trials against MERS. The authors also note it may help against related coronaviruses, including the new virus then emerging from Wuhan, China. Animal results of this strength are the usual gate before human testing.
Catalog record
| CREATOR | de Wit E, Feldmann F, Cronin J, Jordan R, Okumura A, Thomas T, Scott D, Cihlar T, Feldmann H. |
|---|---|
| YEAR | 2020 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 33 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |